trial

Olanzapine Pamoate Depot Versus Oral Olanzapine on Treatment Outcomes in Outpatients With Schizophrenia

NCTId NCT00320489
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Completed
Enrollment 524 (actual)
Sponsored by Eli Lilly and Company
Primary completion 2009-09
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Completed
Enrollment
524 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
None
Start
2006-04
Primary completion
2009-09
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
Olanzapine

Sponsors

Eli Lilly and CompanyLead Sponsor

Investigators

1
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST)Study Director

Sites

49 total
Escondido, United StatesNational City, United StatesOrange, United StatesSan Diego, United StatesWashington D.C., United StatesHonolulu, United StatesChicago, United StatesCedarhurst, United StatesStaten Island, United StatesCanton, United StatesAllentown, United StatesPhiladelphia, United States

Linked catalysts

1
Olanzapine Pamoate Depot Versus Oral Olanzapine on Treatment Outcomes in Outpati — primary completion2009-09

Facts & assertions

4 sourced
Enrollment
524
Phase
PHASE3
Primary Completion Date
2009-09
Status
COMPLETED
relationships
The graph out of here
drug
Olanzapine
drug
lead_sponsor
Eli Lilly and Company
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST)
person